LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

FibroGen Inc

Chiusa

SettoreSettore sanitario

0.31 3.33

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.29

Massimo

0.32

Metriche Chiave

By Trading Economics

Entrata

-13M

4.6M

Vendite

126M

2.7M

EPS

0.05

Margine di Profitto

169.368

Dipendenti

225

EBITDA

77M

-14M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+3233.33% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.1M

30M

Apertura precedente

-3.02

Chiusura precedente

0.31

Notizie sul Sentiment di mercato

By Acuity

56%

44%

327 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

FibroGen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 feb 2025, 11:34 UTC

Acquisizioni, Fusioni, Takeovers

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 feb 2025, 11:34 UTC

Acquisizioni, Fusioni, Takeovers

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 feb 2025, 11:33 UTC

Acquisizioni, Fusioni, Takeovers

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 feb 2025, 11:33 UTC

Acquisizioni, Fusioni, Takeovers

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 feb 2025, 11:31 UTC

Acquisizioni, Fusioni, Takeovers

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 feb 2025, 11:30 UTC

Acquisizioni, Fusioni, Takeovers

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

Confronto tra pari

Modifica del prezzo

FibroGen Inc Previsione

Obiettivo di Prezzo

By TipRanks

3233.33% in crescita

Previsioni per 12 mesi

Media 10 USD  3233.33%

Alto 10 USD

Basso 10 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per FibroGen Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

1

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.306 / 0.33939Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

327 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.